Literature DB >> 20085535

Comprehension of complex discourse in different stages of Huntington's disease.

Charlotta Saldert1, Angelika Fors, Sofia Ströberg, Lena Hartelius.   

Abstract

BACKGROUND: Huntington's disease not only affects motor speech control, but also may have an impact on the ability to produce and understand language in communication. AIMS: The ability to comprehend basic and complex discourse was investigated in three different stages of Huntington's disease. METHODS & PROCEDURES: In this experimental group study, 18 patients with Huntington's disease completed a test that assessed basic language abilities as well as tests from a battery of tasks that explored the ability to comprehend more complex information. The test battery assessed the ability to comprehend logico-grammatical sentences, ambiguous information and inferred meaning on sentence and discourse levels. OUTCOMES &
RESULTS: In comparison with results from pair-matched participants in a control group, matched for gender, age and education, the group of individuals with Huntington's disease had significantly more problems with all tasks requiring more complex cognitive processing. There was a correlation, as well as tendencies towards correlations, between results in the group of individuals with Huntington's disease and stage of the disease. However, results within the stage groups were heterogeneous, and some individuals in an early stage of the disease sometimes performed as well as others in a late stage. CONCLUSIONS & IMPLICATIONS: It is likely that, in complex discourse tasks, individual differences in cognitive capacity may contribute and override other differences related to stage of disease. These results indicate that it is important to assess comprehension even in early stages of Huntington's disease, with tests that are sensitive to subtle language disorders, to reduce communication problems for the individuals concerned and their conversational partners.

Entities:  

Mesh:

Year:  2010        PMID: 20085535     DOI: 10.3109/13682820903494742

Source DB:  PubMed          Journal:  Int J Lang Commun Disord        ISSN: 1368-2822            Impact factor:   3.020


  6 in total

Review 1.  Cognitive impairment in Huntington disease: diagnosis and treatment.

Authors:  Jane S Paulsen
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

2.  Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication.

Authors:  Jan Rusz; Jiří Klempíř; Tereza Tykalová; Eva Baborová; Roman Čmejla; Evžen Růžička; Jan Roth
Journal:  J Neural Transm (Vienna)       Date:  2014-05-09       Impact factor: 3.575

3.  Perceived changes in communicative interaction in atypical parkinsonism.

Authors:  Lena Hartelius; Johan Lindberg; Lena Petersson; Charlotta Saldert
Journal:  ISRN Neurol       Date:  2011-04-13

4.  International Guidelines for the Treatment of Huntington's Disease.

Authors:  Anne-Catherine Bachoud-Lévi; Joaquim Ferreira; Renaud Massart; Katia Youssov; Anne Rosser; Monica Busse; David Craufurd; Ralf Reilmann; Giuseppe De Michele; Daniela Rae; Ferdinando Squitieri; Klaus Seppi; Charles Perrine; Clarisse Scherer-Gagou; Olivier Audrey; Christophe Verny; Jean-Marc Burgunder
Journal:  Front Neurol       Date:  2019-07-03       Impact factor: 4.086

5.  Neural basis of impaired narrative discourse comprehension in prodromal and mild dementia with lewy bodies.

Authors:  Anaïs Falque; Mélanie Jordanis; Lionel Landré; Paulo Loureiro de Sousa; Mary Mondino; Emmanuelle Furcieri; Frédéric Blanc
Journal:  Front Aging Neurosci       Date:  2022-09-15       Impact factor: 5.702

6.  Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Angela Roberts; Praveen Dayalu; Dana L Hanifan; Jennifer A Miner; Daniel Claassen; Emily Mower Provost
Journal:  Qual Life Res       Date:  2020-08-24       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.